THE TRULICITY 1.5 MG DIARIES

The demo reached each its Principal endpoints, with semaglutide 2.four mg demonstrating statistically substantial and outstanding enhancements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH in comparison to placebo.oneThese highlights